Journal article
Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use
Abstract
BACKGROUND: little is known about the incidence and characteristics of multisystem immune-related adverse events (irAEs) associated with dual-agent ipilimumab and nivolumab use.
METHODS: A retrospective cohort review was completed that included cancer patients seen at the Juravinski Cancer Centre who received at least one dose of ipilimumab and nivolumab from 2018 to 2022. Patient characteristics, cancer types, and irAEs were recorded. …
Authors
Li Y; Pond G; McWhirter E
Journal
Current Oncology, Vol. 31, No. 1, pp. 425–435
Publisher
MDPI
DOI
10.3390/curroncol31010028
ISSN
1198-0052